These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21506642)

  • 21. Virus-like particles: designing an effective AIDS vaccine.
    Young KR; McBurney SP; Karkhanis LU; Ross TM
    Methods; 2006 Sep; 40(1):98-117. PubMed ID: 16997718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza virosomes as an efficient system for adjuvanted vaccine delivery.
    Glück R; Moser C; Metcalfe IC
    Expert Opin Biol Ther; 2004 Jul; 4(7):1139-45. PubMed ID: 15268680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
    Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
    Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses.
    Kammer AR; Amacker M; Rasi S; Westerfeld N; Gremion C; Neuhaus D; Zurbriggen R
    Vaccine; 2007 Oct; 25(41):7065-74. PubMed ID: 17766014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
    Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T
    Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
    Puig Barberà J; González Vidal D
    Expert Rev Vaccines; 2007 Oct; 6(5):659-65. PubMed ID: 17931147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virus-like particle vaccines and adjuvants: the HPV paradigm.
    Buonaguro FM; Tornesello ML; Buonaguro L
    Expert Rev Vaccines; 2009 Oct; 8(10):1379-98. PubMed ID: 19803760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends.
    Badiee A; Heravi Shargh V; Khamesipour A; Jaafari MR
    Vaccine; 2013 Jan; 31(5):735-49. PubMed ID: 23219436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine.
    Herzog C; Hartmann K; Künzi V; Kürsteiner O; Mischler R; Lazar H; Glück R
    Vaccine; 2009 Jul; 27(33):4381-7. PubMed ID: 19450630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.
    Salleras L; Domínguez A; Pumarola T; Prat A; Marcos MA; Garrido P; Artigas R; Bau A; Brotons J; Bruna X; Català P; Carreras E; Cuadra D; Gatell A; Millet S; Oller J; Raga E
    Vaccine; 2006 Nov; 24(44-46):6638-42. PubMed ID: 16842892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems.
    Lingnau K; Riedl K; von Gabain A
    Expert Rev Vaccines; 2007 Oct; 6(5):741-6. PubMed ID: 17931154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
    Pushko P; Tumpey TM; Van Hoeven N; Belser JA; Robinson R; Nathan M; Smith G; Wright DC; Bright RA
    Vaccine; 2007 May; 25(21):4283-90. PubMed ID: 17403562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine.
    Soema PC; Rosendahl Huber SK; Willems GJ; Jiskoot W; Kersten GF; Amorij JP
    Pharm Res; 2015 Apr; 32(4):1505-15. PubMed ID: 25344321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
    Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
    Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
    Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunostimulating reconstituted influenza virosomes.
    Zurbriggen R
    Vaccine; 2003 Feb; 21(9-10):921-4. PubMed ID: 12547603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR; Colberg K; Frick M; Preusche A
    Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.